3SBio (OTCMKTS:TRSBF – Get Free Report) is projected to post its results before the market opens on Monday, March 30th. Analysts expect 3SBio to post earnings of $0.5160 per share and revenue of $1.9761 billion for the quarter.
3SBio Stock Performance
OTCMKTS TRSBF opened at $2.61 on Friday. 3SBio has a 12 month low of $2.22 and a 12 month high of $4.74. The company’s 50-day moving average price is $2.80 and its 200-day moving average price is $3.37.
3SBio Company Profile
3SBio Inc (OTCMKTS: TRSBF) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of protein-based therapeutics and chemical drugs. Established in 1999 and headquartered in Shenyang, Liaoning Province, the company has built an integrated platform that encompasses in-house R&D capabilities, clinical development, commercial production and a nationwide sales network.
The company’s product portfolio features a range of hematopoietic growth factors such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO), insulin and insulin analogs, hemostasis agents and monoclonal antibodies.
Read More
Receive News & Ratings for 3SBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 3SBio and related companies with MarketBeat.com's FREE daily email newsletter.
